ACAD β€” ACADIA PHARMACEUTICALS INC

Ownership history in HRT FINANCIAL LP  Β·  13 quarters on record

This page tracks every 13F SEC filing in which HRT FINANCIAL LP reported a position in ACADIA PHARMACEUTICALS INC (ACAD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.14% (2020 Q2)
πŸ“Š Avg. % of fund
0.03%
πŸ“… First filed
2020 Q2
πŸ“… Last filed
2025 Q3
⏱ Quarters held
13

Position Intelligence

HRT FINANCIAL LP Γ— ACAD AI Analytics

πŸ“‰ HRT FINANCIAL LP underperformed the S&P 500 by –9.3% annually on this ACAD position. Timing score: 58% (7/12 decisions correct). Average cost basis: $26.17. Maximum drawdown during holding period: –70.9%.

πŸ“ˆ Position Alpha vs SPY
-9.3%
annualised excess return

❌ Significantly underperformed the S&P 500 by 9.3% ann.
7 quarters analyzed

⏱️ Timing Score
58%

βœ… Decent timing β€” more right than wrong on entries and exits.
7 of 12 add/trim decisions correct

πŸ’° Entry Quality
$26.17
-18.5% vs current ($21.34)

Best entry: $14.09 (2022 Q2)  Β·  Worst: $48.47 (2020 Q2)

πŸ›‘οΈ Drawdown Resilience
–70.9%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
54%
buy-side decisions

7 adds Β· 6 trims. Bought during 3 of 6 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 0.0% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    ACAD price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 40,070 -52,856 -56.9% 0.00% $855K $21.34
2024 Q4 ADDED 92,926 +40,558 +77.4% 0.01% $1.7M $18.35
2024 Q3 REDUCED 52,368 -123,451 -70.2% 0.00% $805K $15.38
2024 Q2 ADDED 175,819 +141,756 +416.2% 0.02% $2.9M $16.25
2024 Q1 REDUCED 34,063 -276,499 -89.0% 0.00% $629K $18.49
2023 Q4 ADDED 310,562 +281,165 +956.4% 0.07% $9.7M $31.31
2023 Q3 REDUCED 29,397 -227,840 -88.6% 0.01% $612K $20.84
2023 Q1 ADDED 257,237 +201,319 +360.0% 0.06% $4.8M $18.82
2022 Q2 ADDED 55,918 +14,020 +33.5% 0.01% $787K $14.09
2022 Q1 REDUCED 41,898 -92,531 -68.8% 0.01% $1.0M $24.22
3 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding ACAD

As of 2025 Q4 β€” sorted by position size

Palo Alto Investors LP 3Y 7Y 9.24% BAKER BROS. ADVISORS LP 3Y 7Y 6.71% Birchview Capital, LP 3Y 7Y 2.67% Nan Fung Group Holdings Ltd 3Y 2.46% Axecap Investments, LLC 2.25% Stonepine Capital Management, LLC 3Y 7Y 1.95% RTW INVESTMENTS, LP 3Y 7Y 1.91% BRAIDWELL LP 3Y 1.74% Logos Global Management LP 3Y 1.37% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.1%
← Back to HRT FINANCIAL LP Holdings